Decision raises the level of diligence drug
companies must maintain to best avoid facing patent infringement suits at times when a drug has reached maximum profitability
Cambridge BioMarketing's Dr. Sam Falsetti discusses CRISPR/Cas9 in rare
diseases and possibilities for the technology in somatic cell vs. germline editing
The associate director in the Product Management group at Taconic Biosciences takes a
look at where CRISPR has been, where it is now, where it is going and what that could all mean for getting the most out of this popular gene-editing
technology
Regardless of
whether it's passive neglect or active erasure, we need to stop leaving out non-Caucasian populations when it comes to cancer research, genome studies and
treatment
It is good news that NIH, FDA and CDC all got funding
boosts in the latest omnibus appropriations legislation, but that should be a foregone conclusion, not something we have to wonder about each and every
year
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.